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S-Adenosyl Methionine Cofactor Modifications Enhance the 
Biocatalytic Repertoire of Small Molecule C-Alkylation 
Iain J. W. McKean,[a,b] Joanna C. Sadler,[a,c] Anibal Cuetos,[d] Amina Frese,[d] Luke D. Humphreys,[c] 
Gideon Grogan,*[d] Paul A. Hoskisson,*[b] Glenn A. Burley*[a]  
Abstract: A tandem enzymatic strategy to enhance the scope of C-
alkylation of small molecules via the in situ formation of S-adenosyl 
methionine (SAM) cofactor analogues is described. A solvent-
exposed channel present in the SAM-forming enzyme SalL tolerates 
5'-chloro-5’-deoxyadenosine (ClDA) analogues modified at the 2-
position of the adenine nucleobase. Coupling SalL-catalyzed 
cofactor production with C-(m)ethyl transfer to coumarin substrates 
catalyzed by the methyltransferase (MTase) NovO forms C-
(m)ethylated coumarins in superior yield and greater substrate scope 
relative to that obtained using cofactors lacking nucleobase 
modifications. Establishing the molecular determinants which 
influence C-alkylation provides the basis to develop a late-stage 
enzymatic platform for the preparation of high value small molecules.   
Regiospecific methylation is an essential process used in Nature 
to modulate biological function. [1, 2] From an industrial 
perspective, methylation of small molecules is a powerful 
strategy to fine-tune their physicochemical properties and 
enhance overall drug potency.[3] In order to fully exploit this 
‘magic methyl effect’ across the pharmaceutical and 
biotechnology sectors,[4, 5] robust methods are required to 
precisely methylate - and indeed alkylate - substrates in an 
environmentally benign manner.[5-7]   
Traditional synthetic approaches have typically involved using 
Friedel-Crafts,[8] radical-based methods,[9, 10] and more recently, 
transition-metal catalyzed activation of C(sp2)-H bonds.[11-13]  
However, obtaining regiospecificity, particularly when this is 
required at a late-stage in a synthetic workflow, is an enduring 
challenge.[3] In contrast, MTases catalyze regiospecific C-
methylation of biomolecules using the SAM cofactor as the 
corresponding methyl donor.[14-17]   
The repertoire of C-methylation extends to small molecules, 
which opens up opportunities to tailor these enzymes as a 
general platform for biocatalytic C-C bond formation (Figure 1a). 
A representative example is NovO, which catalyzes the C-
alkylation of coumarins (e.g. 1), and forms a key step in the 
biosynthesis of Novobiocin.[18-20]  A hallmark of NovO is its 
substrate promiscuity (e.g., 1) and the ability to utilize S-
alkylated analogues of SAM to form products such as 2 (Figure 
1a).[20, 21] 
 
Figure 1. Biocatalytic C-alkylation using (a) S-alkylated SAM analogues, and 
(b) a tandem enzymatic process. (c) Enhancement of yield and substrate 
scope of C-(m)ethylation by modifications to the cofactor scaffold.  Ade = 
adenine.  
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One limitation of this process is the need to prepare these 
cofactors by chemical synthesis, which is laborious, low yielding 
and produces both epimers at the sulfur centre.[22-26]  
Additionally, SAM analogues are inherently unstable in buffered 
solution (t1/2 942 min for SAM at pH 8).
[27, 28]  A more step- and 
atom-efficient strategy is to couple cofactor formation with C-
alkyl transfer.[15, 29, 30] One example of this one-pot process is the 
generation of cofactor analogues in situ from either ClDA or ATP 
and (m)ethionine,[15, 29-33] followed by C-(m)ethyl transfer 
catalyzed by a MTase (Figure 1b).[34] ClDA is a shelf-stable, 
atom-economical adenosine source for such a process 
catalyzed by SalL compared to ATP, which is a substrate for 
SAM production by methionine adenosyltransferase (MAT).[15, 27, 
29, 35, 36]  
Although in-depth knowledge of the substrate promiscuity of C-
MTases has been garnered from structural and mutagenesis 
studies,[17, 19, 20, 37] little is known about how the structural 
features of the SAM cofactor itself influences the yield and 
scope of C-alkylation.[14, 30] Herein, we showcase a method to 
address these limitations by strategic modifications to SAM and 
S-adenosyl ethionine (SAE, Figure 1c).   
An earlier structural study of SalL in complex with ClDA and 
methoinine revealed a solvent-exposed channel into the active 
site.[38-40] To explore this in more detail, we obtained two 
structures of wild-type SalL with SAM and chloride (6RYZ, 1.50 
Å), and with ClDA alone (6RZ2, 1.77 Å; Figure 2, Table S1). 
One significant difference in our structures compared to those 
obtained previously was a rotation of the sidechain of Arg243, 
from the solvent exposed exterior of the protein to the interior of 
the active site, enabling the formation of electrostatic 
interactions between Arg243 and the carboxylate of SAM 
(Figure 2, S1), and the side chain of Glu17 from the adjacent 
monomer. No associated changes in the solvent exposed 
channel were observed. These structures were then used as a 
guide for the preparation of point mutants in order to explore the 
roles of specific residues in catalysis. Phe186Leu, Trp129Phe, 
Asp183Glu, Trp190Ala, Val12Met and Tyr70Met displayed a 
reduced level of activity relative to wildtype SalL (Table S2, 
Figure S2). The Phe186Leu mutant was able to form SAM and 
SAM analogues, albeit in slightly poorer conversions relative to 
the wildtype (Figure S15). In contrast, enzymatic activity was 
abolished in the Asp183Ala, Asn188Ala, Phe186Ala and 
Phe228Ile/Ala mutants. This suggests that -stacking between 
Phe228 and the adenine nucleobase, the electrostatic 
interaction between the Met carboxylate and Asp183, and H-
bonding to the Hoogsteen face of the adenine nucleobase 
(Asn188) are essential for catalysis.   
Further supporting evidence for the importance of Asp183 for 
catalysis was observed when a tetrazole carboxylic acid 
bioisostere of methionine was used (Figure 3a). The use of 
tetMet[27] resulted in 99% conversion to 4c, despite slower 
reaction kinetics relative to SAM formation (4a, Figure 3b, Table 
S3, Figures S8-12, S14). However, an increase in steric bulk at 
the sulfur center i.e., by replacing Met with L-ethionine formed 
SAE (4b) albeit in lower conversion (41%) relative to SAM.   
 
Figure 2. WT SalL in complex with ClDA and L-Met (PDB 2Q6I[31]) 
superimposed with WT SalL in complex with SAM (6RYZ, this study). 
Neighbouring monomers and amino acid side-chains of 2Q6I are shown in 
cyan and light blue. Arg243 and SAM (6RYZ, coral) illustrate relocation of this 
side chain to form new ionic interactions (coral) with the SAM carboxylate and 
the side chain of Glu17.  
Replacing adenine with 7-deazaadenine (4d) resulted in only 
10% conversion (Figure 3c),[27] whereas a hypoxanthine 
nucleobase did not form 4e. This suggests that the interaction 
between the N7 of adenine and Asn188 is critical for the 
catalytic function of SalL. High conversions to 4f-j were 
observed using analogues containing modifications to the 2- and 
6-position of adenine. Combining 2,6-diamino or 2-chloro-6-
aminoadenine modifications with tetMet produced 4k and 4l in > 
99% and 41% conversion, respectively (Figure 3d). Although no 
formation of 4m was observed when tetethionine was used, SAE 
analogues 4n and 4o were formed in 78% and 37%, 
respectively. Finally, no cofactor products were formed using 
ClDA substrates lacking either 2伴/3伴 ribose hydroxyl groups.  
Inspection of the crystal structure of NovO in complex with S-
adenosylhomocysteine (SAH) revealed the presence of a 
hydrophobic cleft with a volume of ~ 21 Å3.[18] This is in the exact 
location of the 2-position of the adenine nucleobase (Figure 4, 
S3). We surmised that SAM/SAE cofactors bearing 
modifications of complementary steric volume at this position 
would also be substrates for NovO. Our tandem enzymatic 
process using purified SalL and NovO in the presence of  
stoichiometric amounts of ClDA analogue, L-Met and coumarin 
(5) indeed demonstrated the enhanced conversion of methylated 
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coumarin (5a) via the in situ formation of modified SAM 
analog
ues 
relative 
to SAM (Figure S70; Table S5).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. (a) Formation of SAM/SAE analogues catalyzed by SalL. (b) Reaction kinetics and % conversions using modified Met analogues. Substrate scope of 
cofactor synthesis incorporating (c) nucleobase and (d) a combination of nucleobase and amino acid modifications. Assay conditions: ClDA/ClDA analogue (400 
µM), L-Met/L-Ethionine (2.00 mM), SalL (2.10 M), DTT (1.00 mM) and BSA (1.00 mg/mL), potassium phosphate buffer (100 mM, pH 6.8), 24 h, 37 ºC. % 
conversions determined by RP-HPLC using a ratio of the peak area (254 nm) of the ClDA analogue to SAM/SAE analogue and 5ガ-methylthioadenosine (or 
analogue).[27] 
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Figure 4. Crystal structure of NovO in complex with SAH highlighting the 2-
position of adenine projecting towards a hydrophobic cleft (red. PDB: 5MGZ). 
Figure 5. C-(m)ethylation of 5 catalyzed by NovO using modified cofactors. 
For example, using analogues 4h or 4j formed in situ, enhanced 
the conversion to 5a from 17% (using SAM) to 53% (4h) and 
39% (4j) was achieved. Further enhancement was achieved 
using an excess of ClDA analogues (2 equiv) and L-Met (10 
equiv.). In this instance, the conversion of 5 to 5a improved to 
85% (4h) and 77% (4j) relative to 49% when SAM was 
generated in situ (Figure 5). As identified in an earlier study, 
MTAN was added to the reaction mixture in order to degrade the 
SAH analogue, which inhibits NovO.[34] The 2-modified alkyne 
cofactor 4i displayed comparable conversion (5a, 50%) to SAM, 
whereas the formation of the 2-amino-6-chloro analogue (4g) in 
situ did not form 5a.Tetrazole analogues 4c, 4k and 4l produced 
significantly lower amounts of 5a relative to SAM. Enhanced 
levels of C-ethylation of 5 was also observed, producing 5b from 
4n (39%) and 4o (25%) relative to only 24% when SAE was 
used. Exploration of the wider scope of methylating (5a-13a) and 
ethylating (5b-13b) a suite of 3-substituted coumarins (5-13) 
exemplified the superiority of using nucleobase-modified 
SAM/SAE analogues (Figure 6).[34] In almost all examples, the 2-
amino and 2-chloro modified cofactors out-performed SAM in 
methylating 5-13. One exception was triazole 11, in which no C-
(m)ethylation was observed using any of the cofactors tested.   
Finally, the ability of our tandem enzymatic process to 
(m)ethylate coumarin scaffolds with known biological activity and 
clinical relevance was explored. The core of coumarin 12a is a 
precursor to a known inhibitor of Hsp90,[41] and is being pursued 
as an anti-cancer therapy,[42] whilst 13a is a metabolite of 
warfarin.[43] C-methylation was almost quantitative, producing 
12a (95% conversion; 23% isolated yield) and 13a (92%) when 
4j was used compared to only 15% (12a) and 7% (13a) 
conversion using SAM.  Ethylation of both substrates produced 
12b and 13b in 21% and 37% respectively. In contrast, 12b was 
formed in only trace amounts (3%), whereas no ethylated 
product (13b) was formed using SAE. 
In summary, we have established a new biocatalytic strategy 
which enhances the yield and substrate scope of small molecule 
C-(m)ethylation by incorporating nucleobase modifications within 
the SAM cofactor. Key to the success of this approach is the 
compatibility of SalL and NovO to couple in situ generation of 
SAM/SAE cofactor analogues (SalL) with C-(m)ethyl transfer 
(NovO). We envisage that blending directed evolution strategies 
with cofactor analogue mapping, and new strategies to recycle 
the SAH product formed by C-alkylation[15, 44] will provide new 
opportunities to identify enzyme variants with wider substrate 
promiscuity. 
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Figure 6. Substrate scope of C-(m)ethylation of coumarins 6-13. ClDA/ClDA analogue (400 M), L-Met/L-ethionine (2.00 mM), coumarin (200 M), SalL (2.10 M), 
DTT (1.00 mM) and BSA (1.00 mg/mL), potassium phosphate buffer (100 mM, pH 6.8), 24 h, 37 ºC then NovO (9.38 M) and MTAN (132 nM).[18, 34] *Optimized 
conditions for 13a/13b with 4j/4o: 2-Cl-ClDA 1.60 mM, L-Met/L-ethionine (8.00 mM), 7-hydroxywarfarin (200 M), SalL (4.20 M), DTT (4.00 mM) and BSA (1.00 
mg/mL), potassium phosphate buffer (100 mM, pH 6.8) 24 h, 37 °C then NovO (42.6 M) and MTAN (528 nM). % conversions were determined by RP-HPLC 
using a ratio of the peak area at 300 nm of the coumarin starting material to the product.[18, 34] 
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